Mawer Investment Management Ltd. Buys 27,843 Shares of Zoetis Inc. $ZTS

Mawer Investment Management Ltd. lifted its stake in Zoetis Inc. (NYSE:ZTS) by 8.5% in the fourth quarter, HoldingsChannel.com reports. The fund owned 354,445 shares of the company’s stock after purchasing an additional 27,843 shares during the period. Mawer Investment Management Ltd.’s holdings in Zoetis were worth $44,596,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the stock. Nordea Investment Management AB boosted its holdings in shares of Zoetis by 79.2% in the fourth quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock worth $622,222,000 after buying an additional 2,179,578 shares during the last quarter. Seilern Investment Management Ltd boosted its holdings in shares of Zoetis by 361.2% in the fourth quarter. Seilern Investment Management Ltd now owns 333,465 shares of the company’s stock worth $41,957,000 after buying an additional 261,155 shares during the last quarter. Assenagon Asset Management S.A. boosted its holdings in shares of Zoetis by 134.4% in the fourth quarter. Assenagon Asset Management S.A. now owns 1,631,619 shares of the company’s stock worth $205,290,000 after buying an additional 935,432 shares during the last quarter. AE Wealth Management LLC boosted its holdings in shares of Zoetis by 71.3% in the fourth quarter. AE Wealth Management LLC now owns 144,531 shares of the company’s stock worth $18,185,000 after buying an additional 60,167 shares during the last quarter. Finally, Prudential PLC boosted its holdings in shares of Zoetis by 17.7% in the third quarter. Prudential PLC now owns 197,852 shares of the company’s stock worth $28,950,000 after buying an additional 29,702 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors.

Trending Headlines about Zoetis

Here are the key news stories impacting Zoetis this week:

• Negative Sentiment: Multiple law firms, including Rosen, Kaplan Fox, Levi & Korsinsky, Robbins LLP, Frank R. Cruz, and Robbins Geller, announced or reminded investors about a class action lawsuit tied to Zoetis securities purchases between January 14, 2025 and May 6, 2026. These updates highlight the July 27, 2026 lead-plaintiff deadline and keep the litigation risk in focus. Article Title
• Negative Sentiment: One lawsuit notice alleges Zoetis’ risk disclosures were too generic and failed to warn investors about known safety and competition issues, suggesting possible shareholder harm and adding to uncertainty around the company’s legal and operational outlook. Article Title
• Neutral Sentiment: A Yahoo Finance item flagged Zoetis as one of the most oversold S&P 500 stocks so far in 2026, which may reflect weak sentiment but does not itself provide a new company-specific catalyst. Article Title

Insider Buying and Selling

In other Zoetis news, Director Paul Bisaro purchased 2,000 shares of Zoetis stock in a transaction that occurred on Wednesday, May 13th. The shares were bought at an average price of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the transaction, the director owned 27,862 shares of the company’s stock, valued at approximately $2,114,168.56. This trade represents a 7.73% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Michael B. Mccallister purchased 3,000 shares of Zoetis stock in a transaction that occurred on Monday, May 11th. The stock was acquired at an average price of $77.76 per share, for a total transaction of $233,280.00. Following the transaction, the director directly owned 24,524 shares of the company’s stock, valued at $1,906,986.24. The trade was a 13.94% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders have acquired 11,650 shares of company stock worth $886,384. Insiders own 0.22% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. Weiss Ratings downgraded shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, March 27th. Leerink Partners reissued a “market perform” rating on shares of Zoetis in a report on Tuesday, March 10th. Wall Street Zen downgraded shares of Zoetis from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Morgan Stanley reissued an “overweight” rating and issued a $115.00 price objective on shares of Zoetis in a report on Friday, May 15th. Finally, Citigroup dropped their price objective on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Six equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $133.92.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $77.61 on Tuesday. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91. Zoetis Inc. has a 1-year low of $72.38 and a 1-year high of $172.23. The company has a market capitalization of $32.54 billion, a P/E ratio of 12.87, a P/E/G ratio of 1.27 and a beta of 0.87. The firm’s 50 day simple moving average is $103.52 and its two-hundred day simple moving average is $116.71.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The firm had revenue of $2.26 billion for the quarter, compared to analysts’ expectations of $2.30 billion. During the same period in the prior year, the firm earned $1.48 EPS. Zoetis’s revenue for the quarter was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Research analysts expect that Zoetis Inc. will post 6.89 EPS for the current fiscal year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be given a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 2.7%. The ex-dividend date is Monday, July 20th. Zoetis’s payout ratio is currently 35.16%.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.